obesity drug news today glp-1 september 22 2025 weight loss drugs leave users low on key nutrients, study finds The GLP-1 Access Gap: Mapping

& Salakhutdinov, R

Two Phase 3 trials for AD109 with similar design to MARIPOSA are ongoing with topline results anticipated in mid-2025

Compound: Semaglutide Format: Lyophilized peptide research vial Research Category: GLP-1 receptor pathway peptide research Research Focus: GLP-1 receptor signaling, incretin biology, glucose-response models, insulinotropic pathway research, appetite-associated pathway studies, gastric-emptying pathway models, adipose-associated signaling, metabolic adaptation, and energy-balance biology

Additionally, specificity was utilized to assess whether some events were associated with specific factors, and coherence was to examine the temporal sequence of events that aligned with a potential relationship

For pipeline context and head-to-head insights, see Orforglipron vs Rybelsus for how next-generation oral options may compare in practice, and follow Orforglipron Clinical Trials for updated results and milestones

Democrats are more likely to favor this proposal than Republicans or independents